NCT01498874

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Gevokizumab in Subjects With Moderate to Severe Acne Vulgaris

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 127 (actual)
• Sponsor: XOMA (US) LLC · Industry
• Sex: All
• Age: 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	Placebo	Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
DRUG	gevokizumab	Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
DRUG	gevokizumab	Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

Timeline

• Start date: 2011-12-01
• Primary completion: 2013-04-01
• Completion: 2013-06-01
• First posted: 2011-12-26
• Last updated: 2014-03-04

Locations

19 sites across 1 country: United States